Teva's Counterclaims Against ADHD Patent To Stand
A federal judge has denied a bid by Elan Corporation Plc to dismiss counterclaims from defendant Teva Pharmaceuticals USA Inc. in a patent dispute over the attention deficit hyperactivity disorder drug...To view the full article, register now.
Already a subscriber? Click here to view full article